Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
Prostate-specific membrane antigen is a type II membrane protein with folate hydrolase activity produced by prostatic epithelium. It has been demonstrated that prostate-specific membrane antigen over-expression may be correlated with prostate cancer, particularly in advanced cancer. The aim of the current study was to explore the possibility of prostate-specific membrane antigen as a therapeutic target for the treatment of prostate cancer. To address this problem, lentivirus-mediated small interfering RNA was employed to reduce endogenous prostate-specific membrane antigen expression in prostate cancer cell lines—LNCaP and DU-145. Then, the tumorigenesis, migration ability and invasiveness of prostate-specific membrane antigen-reduced prostate cancer cell lines were also examined. The prostate-specific membrane antigen expression in LNCaP and DU-145 cells was persistently and markedly reduced by lentivirus-mediated RNA interference. Down-regulation of prostate-specific membrane antigen expression significantly suppressed the growth rates of LNCaP and DU-145 cells. Moreover, the specific down-regulation arrested cells in G0/G1 phase of cell cycle. Furthermore, we also observed that the silence of prostate-specific membrane antigen could decrease the migration ability and the invasiveness of LNCaP and DU-145 cells. Our investigation demonstrated that lentivirus-mediated RNA interference silencing targeting prostate-specific membrane antigen might reduce the proliferation, and induce potent antitumor activity of LNCaP and DU-145 cells. Prostate-specific membrane antigen has considerable potential as a new therapeutic target for the treatment of prostate cancer.
Guo
Zhenghui
Z
Department of Urology, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Huang
Hai
H
Zeng
Lexiang
L
Du
Tao
T
Xu
Kewei
K
Lin
Tianxin
T
Jiang
Chun
C
Dong
Wen
W
Cao
Yi
Y
Chen
Jieqing
J
Zhong
WeiDe
W
Huang
Jian
J
D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics*; D049109:Cell Proliferation; D002469:Cell Separation; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D008297:Male; D009361:Neoplasm Invasiveness / Q000235:genetics*; D017430:Prostate-Specific Antigen / Q000037:antagonists & inhibitors* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D034622:RNA Interference; D034741:RNA, Small Interfering; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
D034741:RNA, Small Interfering; D017430:Prostate-Specific Antigen
Cancer Invest. 1989;7(2):179-92
2676086
Gene Ther. 2005 Jul;12(14):1089-98
16003340
Semin Urol Oncol. 1998 Feb;16(1):2-12
9508077
Cancer Res. 1994 Apr 1;54(7):1807-11
7511053
Prostate. 2006 Nov 1;66(15):1641-52
16927306
Nature. 2002 Jul 11;418(6894):244-51
12110901
N Engl J Med. 2003 Jul 24;349(4):366-81
12878745
Nat Protoc. 2006;1(1):234-40
17406238
Leuk Res. 2009 Aug;33(8):1114-9
19036441
J Transl Med. 2008 Oct 04;6:55
18834541
Urology. 1998 Oct;52(4):637-40
9763084
Hematology Am Soc Hematol Educ Program. 2007;:473-81
18024667
Curr Hematol Rep. 2005 Jul;4(4):300-4
16009045
Prostate Cancer Prostatic Dis. 2002;5(1):36-46
15195129
Br J Cancer. 2006 Nov 6;95(9):1186-94
17077805
Mod Pathol. 2008 May;21 Suppl 2:S44-55
18437173
J Urol. 1998 Dec;160(6 Pt 2):2396-401
9817391
Neoplasia. 2006 Nov;8(11):917-24
17132223
Cancer Res. 1997 Jun 15;57(12):2321-4
9192800
Hum Pathol. 2007 May;38(5):696-701
17320151
Am J Physiol Cell Physiol. 2005 May;288(5):C975-81
15840561
BMJ. 2008 Mar 15;336(7644):610-2
18340076
Trends Biotechnol. 2003 Mar;21(3):117-22
12628368
J Pharm Pharmacol. 2008 Apr;60(4):405-13
18380911
Prostate. 2004 Feb 1;58(2):200-10
14716746
Clin Cancer Res. 2003 Dec 15;9(17):6357-62
14695135
Urol Oncol. 2009 Sep-Oct;27(5):539-47
18639471
Jpn J Clin Oncol. 2003 Jan;33(1):1-5
12604715
Urology. 2001 Jun;57(6):1179-83
11377343